Dipraglurant (ADX48621) Dystonia

Preclinical data first published in December 2009 show that Dipraglurant (ADX48621), a metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM), effectively reduced dystonia in a well-known preclinical model of Parkinson’s disease levodopa-induced dyskinesia (PD-LID). Scientific research indicates that the biological causes of different kinds of dystonia is similar –  essentially, because dipraglurant works for one kind of dystonia (i.e. a model of PD-LID), then it has a chance of working for other types of dystonia.